Alicia K. Morgans MD, MPHGenitourinary Medical Oncologist, Dana-Farber Cancer Institute, Boston, Massachusetts
Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts. She specializes is investigating complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. She also serves as the Principal Investigator for multiple prostate cancer clinical trials, including the ECOG Phase 3 ERADICATE trial. She is a member of the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and is a member of the cardio-oncology committee of American Heart Association. She is the President of the Medical Advisory Board and the Vice Chair of the Board of Directors of ZERO.
DisclosuresDr. Morgans reports the following:
- Consulting honoraria: Astellas, AstraZeneca, AAA, Bayer, Clovis, Dendreon, Lantheus, Myovant, Pfizer, Merck, Novartis, Sanofi, Seattle Genetics
- Research collaborations support: Bayer, Myovant, Astellas, Seattle Genetics, Sanofi